Gliprip-MV2 Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, enhances pancreatic insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, contributing to better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, minimizing postprandial hyperglycemia. The synergistic action of these agents targets multiple pathophysiological defects in type 2 diabetes, improving both fasting and postprandial blood glucose levels. Gliprip-MV2 Tablet PR is prescribed as an adjunct to diet and exercise when monotherapy or dual therapy has proven insufficient. It is essential to monitor blood glucose regularly to adjust dosage and avoid hypoglycemia. Caution is advised in patients with renal or hepatic impairment, and contraindications include type 1 diabetes, diabetic ketoacidosis, and known hypersensitivity to any component. Common adverse effects may include gastrointestinal disturbances and hypoglycemia. Patient adherence to lifestyle modifications alongside pharmacotherapy enhances therapeutic outcomes. This combination therapy offers a comprehensive approach to glycemic management in type 2 diabetes patients requiring multi-mechanistic intervention.